Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 7/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.55 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.53 |
| ▸ | KDR | P35968 | 4/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.53 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.53 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14905514 | 0.87 | FGFR3 (0.52) | PDGFRBPDGFRAFGFR3KDRFGFR1 | |
| SCHEMBL16134028 | 0.81 | PDGFRB (0.67) | PDGFRBPDGFRAFGFR3KDRFGFR1 | |
| SCHEMBL14905351 | 0.81 | FGFR3 (0.67) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL14901221 | 0.81 | MAPK1 (0.53) | PDGFRBPDGFRAFGFR3KDRFGFR1 | |
| SCHEMBL14905515 | 0.79 | FGFR3 (0.58) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL14905222 | 0.79 | FGFR3 (0.57) | PDGFRBPDGFRAFGFR3KDRFGFR1 | |
| SCHEMBL15884571 | 0.76 | PDGFRB (0.54) | PDGFRBPDGFRAFGFR3KDRMAPK1 | |
| SCHEMBL14906654 | 0.75 | PDGFRB (0.62) | PDGFRBPDGFRAFGFR3KDRFGFR1 | |
| SCHEMBL14905405 | 0.74 | PDGFRB (0.60) | PDGFRBPDGFRAFGFR3KDRFGFR1 | |
| SCHEMBL15256286 | 0.73 | PDGFRB (0.66) | PDGFRBPDGFRAKDRMAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776436-B1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2019-03-13 | — | — | EP | disclosed |
| US-9757364-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2017-09-12 | — | — | US | disclosed |
| US-20170105978-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2017-04-20 | — | — | US | disclosed |
| US-9527844-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2016-12-27 | — | — | US | disclosed |
| US-9309241-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2016-04-12 | — | — | US | disclosed |
| US-20150057293-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-02-26 | — | — | US | disclosed |
| WO-2013061077-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057293-A1 | NEW COMPOUNDS | NQO1, NTPCR, NDC1 | PDGFRB 3569/4885PDGFRA 3281/4885FGFR3 2292/4885 |
| US-20170105978-A1 | NEW COMPOUNDS | NQO1, NTPCR, NDC1 | PDGFRB 3569/4885PDGFRA 3281/4885FGFR3 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.